The gene-editing technology developer received further support from SoftBank Vision Fund 2 to advance its genomics drug discovery platform.

US-based genomic drug developer Tessera Therapeutics secured over $300m in series C funding from investors including internet and telecommunications group SoftBank’s Vision Fund 2 yesterday.

Hanwha Impact Partners, a branch of diversified conglomerate Hanwha, also took part in the round, as did life sciences-focused venture builder Flagship Pioneering, Alaska Permanent Fund Corporation and a subsidiary of Abu Dhabi Investment Authority.

The round was filled out Altitude Life Science Ventures, Cormorant Asset Management, Artis Ventures, Salt Fund, March Capital, T Rowe…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.

Not sure if you have a subscription?
Fernando Moncada Rivera

Fernando Moncada Rivera is a reporter at Global Corporate Venturing and also host of the CVC Unplugged podcast.